Assetmark Inc. Trims Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Assetmark Inc. cut its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 86.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,842 shares of the biopharmaceutical company’s stock after selling 96,746 shares during the period. Assetmark Inc.’s holdings in Amicus Therapeutics were worth $121,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Summit Investment Advisors Inc. raised its stake in Amicus Therapeutics by 4.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 1,280 shares during the period. Diversified Trust Co raised its stake in Amicus Therapeutics by 2.2% during the first quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company’s stock worth $682,000 after purchasing an additional 1,784 shares during the period. Tempus Wealth Planning LLC raised its stake in Amicus Therapeutics by 7.2% during the first quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 1,990 shares during the period. Covestor Ltd raised its stake in Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 2,312 shares during the period. Finally, Stephens Inc. AR raised its stake in Amicus Therapeutics by 27.4% during the first quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 2,938 shares during the period.

Wall Street Analysts Forecast Growth

FOLD has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. UBS Group boosted their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. The Goldman Sachs Group reduced their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Finally, Morgan Stanley raised shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $16.22.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $6.32 on Monday. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The firm’s 50 day moving average price is $6.05 and its 200 day moving average price is $7.42. The company has a market cap of $1.95 billion, a P/E ratio of -52.66 and a beta of 0.53. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.